Geode Capital Management LLC Buys 62,555 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Geode Capital Management LLC grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 8.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 835,790 shares of the company’s stock after buying an additional 62,555 shares during the period. Geode Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $27,494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quest Partners LLC bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth approximately $61,000. Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after purchasing an additional 1,530 shares during the period. FMR LLC raised its position in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares in the last quarter. Finally, Dark Forest Capital Management LP bought a new stake in Tarsus Pharmaceuticals during the second quarter valued at $202,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Finally, The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $54.35 on Friday. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -14.27 and a beta of 1.04. The business has a 50 day moving average of $47.88 and a 200 day moving average of $35.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 1-year low of $18.99 and a 1-year high of $56.77.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.